OSLO, Norway, Nov. 9, 2020 /PRNewswire/ -- Targovax ASA
(OSE: TRVX), a clinical stage immuno-oncology company developing
oncolytic viruses to target hard-to-treat solid tumors, today
announces that the poster "A randomised open-label
phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in
patients with unresectable malignant pleural mesothelioma -
12-month analysis of biomarkers and clinical outcomes" are now
available at the Company's website.
The abstract presents the 12-month analysis of biomarkers and
clinical outcome from the phase I/II trial in malignant pleural
mesothelioma where ONCOS-102 is added to standard of care
chemotherapy (pemetrexed / cisplatin). This analysis supports the
data presented in June.
|
Title
(361):
|
A randomised
open-label phase I/II study adding ONCOS-102 to
pemetrexed/cisplatin in patients with unresectable malignant
pleural mesothelioma - 12-month analysis of biomarkers and clinical
outcomes
|
|
Presenter:
|
Prof. Luis
Paz-Ares, Principal Investigator of the trial and Chair of the
Medical Oncology Department at the Hospital Doce de Octubre,
Madrid
|
|
Poster
session:
Location:
|
Wednesday 11.
November 23:15-23:45 CET (17:15-17:45 EST)
Friday 13.
November 22:40-23:10 CET (16:40-17:10 EST)
Virtual Poster
Hall
|
The poster is also available on Targovax's website.
About SITC Annual Meeting 2020
The Society for Immunotherapy of Cancer's (SITC) 35th
Anniversary Annual Meeting & Pre-Conference Programs (SITC
2020) will be reimagined as a fully VIRTUAL experience this year to
ensure the health and safety of program attendees and their
patients.SITC 2020 provides a multidisciplinary educational and
interactive environment focused on improving cancer patient
outcomes by incorporating strategies based on basic and applied
cancer immunotherapy.
CONTACT:
For further information, please contact:
Renate Birkeli, Investor
Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate
Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
IR enquires:
Kim Sutton Golodetz - LHA Investor
Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-announces-poster-at-the-2020-society-for-immunotherapy-of-cancer--sitc--annual-meeting,c3233804